Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
Rituximab; Viral reactivation; CD20
| Authors: | ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Format: | Article |
| Status: | Published version |
| Publication date: | 2019 |
| Country: | España |
| Institution: | Departament de Salut de la Generalitat de Catalunya (DS) |
| Repository: | Scientia. Dipòsit d'Informació Digital del Departament de Salut |
| OAI Identifier: | oai:scientiasalut.gencat.cat:11351/4691 |
| Online Access: | https://hdl.handle.net/11351/4691 |
| Access Level: | Open access |
| Keyword: | Rituximab Infeccions per VIH Cèl·lules T CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Murine-Derived::Rituximab DISEASES::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections ANATOMY::Hemic and Immune Systems::Hemic and Immune Systems::Immune System::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes::CD4-Positive T-Lymphocytes COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales de origen murino::rituximab ENFERMEDADES::enfermedades del sistema inmune::síndromes de inmunodeficiencia::infecciones por VIH ANATOMÍA::sistemas sanguíneo e inmunológico::sistemas sanguíneo e inmunológico::sistema inmunológico::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T::linfocitos T CD4-positivos |
| _version_ | 1878729618297454592 |
|---|---|
| author | Serra Peinado, Carla |
| author2 | Grau Exposito, Judit Luque Ballesteros, Laura Navarro Mercadé, Jordi Gallego Rodriguez, Jenny Carolina Martin Castillo, Mario Curran Fàbregas, Adria Burgos Cibrian, Joaquin Ribera Pascuet, Esteve Raventos Roca, Berta Willekens Morales, Rein Nicolas Torrella Domingo, Ariadna Planas Ribas, Bibiana Badía Royes, Rosa María Castellví Vives, Josep Genesca Ferrer, Meritxell Falcó Ferrer, Vicenç Buzón Gómez, María José Astorga Gamaza, Antonio |
| author2_role | author author author author author author author author author author author author author author author author author author |
| author_browse | Astorga Gamaza, Antonio Badía Royes, Rosa María Burgos Cibrian, Joaquin Buzón Gómez, María José Castellví Vives, Josep Curran Fàbregas, Adria Falcó Ferrer, Vicenç Gallego Rodriguez, Jenny Carolina Genesca Ferrer, Meritxell Grau Exposito, Judit Luque Ballesteros, Laura Martin Castillo, Mario Navarro Mercadé, Jordi Planas Ribas, Bibiana Raventos Roca, Berta Ribera Pascuet, Esteve Serra Peinado, Carla Torrella Domingo, Ariadna Willekens Morales, Rein Nicolas |
| author_facet | Serra Peinado, Carla Grau Exposito, Judit Luque Ballesteros, Laura Navarro Mercadé, Jordi Gallego Rodriguez, Jenny Carolina Martin Castillo, Mario Curran Fàbregas, Adria Burgos Cibrian, Joaquin Ribera Pascuet, Esteve Raventos Roca, Berta Willekens Morales, Rein Nicolas Torrella Domingo, Ariadna Planas Ribas, Bibiana Badía Royes, Rosa María Castellví Vives, Josep Genesca Ferrer, Meritxell Falcó Ferrer, Vicenç Buzón Gómez, María José Astorga Gamaza, Antonio |
| author_role | author |
| collection | Scientia. Dipòsit d'Informació Digital del Departament de Salut |
| description | Rituximab; Viral reactivation; CD20 |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_0b82e9302c4a6b3eb43b4fb2822c01ac |
| institution | Departament de Salut de la Generalitat de Catalunya (DS) |
| instname_str | Departament de Salut de la Generalitat de Catalunya (DS) |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:scientiasalut.gencat.cat:11351/4691 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Nature Publishing Group |
| publisherStr | Nature Publishing Group |
| reponame_str | Scientia. Dipòsit d'Informació Digital del Departament de Salut |
| spelling | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab Serra Peinado, Carla Grau Exposito, Judit Luque Ballesteros, Laura Navarro Mercadé, Jordi Gallego Rodriguez, Jenny Carolina Martin Castillo, Mario Curran Fàbregas, Adria Burgos Cibrian, Joaquin Ribera Pascuet, Esteve Raventos Roca, Berta Willekens Morales, Rein Nicolas Torrella Domingo, Ariadna Planas Ribas, Bibiana Badía Royes, Rosa María Castellví Vives, Josep Genesca Ferrer, Meritxell Falcó Ferrer, Vicenç Buzón Gómez, María José Astorga Gamaza, Antonio Rituximab Infeccions per VIH Cèl·lules T CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Murine-Derived::Rituximab DISEASES::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections ANATOMY::Hemic and Immune Systems::Hemic and Immune Systems::Immune System::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes::CD4-Positive T-Lymphocytes COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales de origen murino::rituximab ENFERMEDADES::enfermedades del sistema inmune::síndromes de inmunodeficiencia::infecciones por VIH ANATOMÍA::sistemas sanguíneo e inmunológico::sistemas sanguíneo e inmunológico::sistema inmunológico::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T::linfocitos T CD4-positivos Rituximab; Viral reactivation; CD20 Rituximab; Reactivació viral; CD20 Rituximab; Reactivación viral; CD20 The identification of exclusive markers to target HIV-reservoir cells will represent a significant advance in the search for therapies to cure HIV. Here, we identify the B lymphocyte antigen CD20 as a marker for HIV-infected cells in vitro and in vivo. The CD20 molecule is dimly expressed in a subpopulation of CD4-positive (CD4+) T lymphocytes from blood, with high levels of cell activation and heterogeneous memory phenotypes. In lymph node samples from infected patients, CD20 is present in productively HIV-infected cells, and ex vivo viral infection selectively upregulates the expression of CD20 during early infection. In samples from patients on antiretroviral therapy (ART) this subpopulation is significantly enriched in HIV transcripts, and the anti-CD20 monoclonal antibody Rituximab induces cell killing, which reduces the pool of HIV-expressing cells when combined with latency reversal agents. We provide a tool for targeting this active HIV-reservoir after viral reactivation in patients while on ART. This study was supported by the American National Institutes of Health (grant R21AI118411 to M.B.), the Spanish Secretariat of Science and Innovation and FEDER funds (grant SAF2015-67334-R [MINECO/FEDER]), the Spanish "Ministerio de Economia y Competitividad, Instituto de Salud Carlos III" (ISCIII, PI17/01470), GeSIDA and the Spanish AIDS network Red Tematica Cooperativa de Investigacion en SIDA (RD16/0025/0007). M.B. is supported by the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). M.G. is supported by the "Pla estrategic de recerca i innovacio en salut" (PERIS), from the Catalan Government. Nature Publishing Group https://hdl.handle.net/11351/4691 |
| spellingShingle | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab Serra Peinado, Carla Rituximab Infeccions per VIH Cèl·lules T CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Murine-Derived::Rituximab DISEASES::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections ANATOMY::Hemic and Immune Systems::Hemic and Immune Systems::Immune System::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes::CD4-Positive T-Lymphocytes COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales de origen murino::rituximab ENFERMEDADES::enfermedades del sistema inmune::síndromes de inmunodeficiencia::infecciones por VIH ANATOMÍA::sistemas sanguíneo e inmunológico::sistemas sanguíneo e inmunológico::sistema inmunológico::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T::linfocitos T CD4-positivos |
| status_str | publishedVersion |
| title | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab |
| title_full | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab |
| title_fullStr | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab |
| title_full_unstemmed | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab |
| title_short | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab |
| title_sort | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab |
| topic | Rituximab Infeccions per VIH Cèl·lules T CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Murine-Derived::Rituximab DISEASES::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections ANATOMY::Hemic and Immune Systems::Hemic and Immune Systems::Immune System::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes::CD4-Positive T-Lymphocytes COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales de origen murino::rituximab ENFERMEDADES::enfermedades del sistema inmune::síndromes de inmunodeficiencia::infecciones por VIH ANATOMÍA::sistemas sanguíneo e inmunológico::sistemas sanguíneo e inmunológico::sistema inmunológico::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T::linfocitos T CD4-positivos |
| topic_facet | Rituximab Infeccions per VIH Cèl·lules T CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Murine-Derived::Rituximab DISEASES::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections ANATOMY::Hemic and Immune Systems::Hemic and Immune Systems::Immune System::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes::CD4-Positive T-Lymphocytes COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales de origen murino::rituximab ENFERMEDADES::enfermedades del sistema inmune::síndromes de inmunodeficiencia::infecciones por VIH ANATOMÍA::sistemas sanguíneo e inmunológico::sistemas sanguíneo e inmunológico::sistema inmunológico::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T::linfocitos T CD4-positivos |
| url | https://hdl.handle.net/11351/4691 |